[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-suspected-or-confirmed\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-suspected-or-confirmed":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,72,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100625752","a-study-measuring-markers-of-airway-inflammation-in-breath-samples-from-people-with-respiratory-diseases-and-healthy-volunteers-100625752",false,"NCT07426718","A Study Measuring Markers of Airway Inflammation in Breath Samples From People With Respiratory Diseases and Healthy Volunteers.","An Expanded inVestigation of Inflammacheck™ to Measure Exhaled Breath CondensaTe Hydrogen perOxide in RespiratorY Conditions A Cross-sectional, Observational Study Comparing Exhaled Breath Biomarkers Across Respiratory Diseases and Healthy Volunteers.","VICTORY 2","Inclusion Criteria:\n\n\\- 1. Age: Adults aged ≥18 years. 2. Consent: Willing and able to provide written informed consent (prospective participants only).\n\n3\\. Clinical status: Belong to one of the defined diagnostic categories listed below:\n\n1. Group A: Lung cancer confirmed by multidisciplinary team (MDT) diagnosis.\n2. Group B: Suspected lung cancer (biopsy negative or awaiting further investigation).\n3. Group C: Pneumonia (radiologically or clinically confirmed).\n4. Group D: Non-malignant airways diseases (asthma or COPD).\n5. Group E: Other non-malignant respiratory diseases (interstitial lung disease, bronchiectasis, breathing pattern disorder).\n6. Group F: Healthy controls with no known respiratory disease. 4. Clinical documentation: Availability of relevant diagnostic and demographic data to confirm disease classification (for retrospective participants).\n\n   5\\. Previous participation: Individuals previously enrolled in the VICTORY or ExPeL studies may be included for retrospective data integration.\n\n   6\\. Willing and able to perform a breath test using the Inflammacheck® device. 7. Willing to allow access to relevant clinical data and imaging results 8. Be able to understand and communicate in English with or without the need for a translator, to ensure informed consent and comprehension of study procedures\n\n   Exclusion Criteria:\n   * 1\\. Active respiratory infection (e.g., tuberculosis, bronchopneumonia) other than pneumonia (e.g., tuberculosis) at the time of breath sampling.\n\n     2\\. History of major thoracic surgery or lung resection within the previous six months.\n\n     3\\. Current or recent chemotherapy or radiotherapy for lung cancer at the time of breath sampling (except for retrospective confirmed cancer cases where data were collected pre-treatment).\n\n     4\\. Severe cognitive impairment, communication barriers, or any condition preventing informed consent or compliance with study procedures.\n\n     5\\. Pregnancy or breastfeeding. 6. Active use of cannabis or recreational drugs known to alter exhaled breath composition.\n\n     7\\. Current active tobacco smoking within the past 12 hours prior to breath collection will be an exclusion criterion, as will the use of vaping or e-cigarettes within this period, to prevent contamination of exhaled breath samples 8. Participants who have taken systemic antibiotics or commenced a new course of oral or inhaled corticosteroids within the preceding two weeks will also be excluded, as these may transiently alter inflammatory biomarkers in exhaled breath (this is not applicable to participants with pneumonia). Stable use of maintenance inhaled corticosteroids in patients with chronic respiratory conditions (e.g., asthma, COPD) will be permitted, provided dosing has remained unchanged for at least four weeks prior to sampling.\n\n     9\\. Any condition that, in the opinion of the investigator, could compromise participant safety or the integrity of the data.\n\n     10\\. Unable or unwilling to provide informed consent. 11. Unable to complete the breath test due to physical or cognitive limitations.\n\n     12\\. Currently participating in another interventional clinical trial that may confound breath biomarker data.\n\n     13\\. Received systemic treatment for lung cancer prior to breath sampling (for the lung cancer group only).\n\n     14\\. History of any active cancer within the past 12 months (excluding basal cell carcinoma of the skin or cervical carcinoma in situ), except for those in the confirmed lung cancer group.\n\n     15\\. They have any active respiratory infection other than pneumonia (e.g., tuberculosis) at the time of breath sampling.\n\n     16\\. They have undergone a bronchoscopy or invasive respiratory procedure within the past 48 hours, due to the potential for artefacts in breath data.\n\n     17\\. Pneumonia with concurrent lung cancer, thoracic malignancy or lung fibrosis. Pneumonia with co-existent asthma or COPD can be included at discretion of the PI.",true,"ALL","18 Years",{"count":21,"type":22},140,"ESTIMATED","OBSERVATIONAL","Lung cancer remains the leading cause of cancer-related death in the UK, with over 35,000 deaths annually and most cases diagnosed at a late stage. Current screening programmes using low-dose CT scans target only high-risk individuals, missing around 30% of lung cancer cases, including many women and never-smokers. There is no simple, non-invasive tool to help triage patients with persistent respiratory symptoms who fall outside formal screening criteria. Inflammacheck® measures hydrogen peroxide and other breath biomarkers linked to airway inflammation and oxidative stress. Preliminary studies (VICTORY and ExPeL) have shown strong diagnostic performance for distinguishing lung cancer from other respiratory conditions. VICTORY 2 aims to validate and refine the AI model supporting Inflammacheck®, enabling accurate, rapid, and affordable triage for suspected lung cancer in NHS settings.",[26,27,28,29],"Lung Cancer (Diagnosis)","Lung Cancer (Suspected or Confirmed)","Healthy","Pneumonia","RECRUITING","2026-05-05",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":34},"2026-03-05",{"date":38,"type":22},"2026-12-30",{"name":40,"class":41},"Portsmouth Hospitals NHS Trust","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100633048","one-stop-diagnosis-and-treatment-for-suspected-lung-cancer-combined-rbs-ncle-obct-and-ablation-100633048","NCT07521618","One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation","An Exploratory Clinical Trial on the Integration of Detection, Sampling and Treatment of Peripheral Lung Cancer by Robotic Bronchoscopy System","One-stop","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* High-risk pulmonary nodule\u002Ftumor maximum diameter ≤3 cm.\n* Lesion judged suitable for bronchial navigation-guided diagnosis and treatment.\n* Ineligible for surgery or refuses surgery\u002Fradiotherapy; agrees to primary ablation therapy; provides written informed consent.\n\nExclusion Criteria:\n\n* Diffuse bilateral lung lesions unresponsive to ablation.\n* Contraindication to bronchoscopy or inability to tolerate\u002Fcooperate with bronchoscopy.\n* Severe bleeding tendency or irreversible coagulopathy (PT \\>18 s, PTA \\\u003C40%).Platelet count \\\u003C70×10⁹\u002FL; anticoagulant\u002Fantiplatelet therapy discontinued \\\u003C1 week before ablation (except prophylactic low-molecular-weight heparin).\n* Severe pulmonary impairment (maximal voluntary ventilation \\\u003C40%).\n* Other metastatic tumors with widespread metastasis; life expectancy \\\u003C3 months.\n* Poor general condition: widespread metastasis, severe infection, high fever, infectious\u002Fradiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic\u002Fnutritional disorders.\n* Eastern Cooperative Oncology Group (ECOG) performance status \\>2.\n* Target lesion received radiotherapy within the past 6 months.\n* Active hepatitis B, active hepatitis C, known HIV-1\u002F2 antibody positivity, or other active infections judged by the investigator to interfere with treatment.\n* History of epilepsy, psychosis, or cognitive impairment.\n* Pregnant\u002Flactating females; males or females planning conception during the trial.\n* Other conditions deemed inappropriate by the investigator.",{"count":52,"type":22},30,"INTERVENTIONAL",[55],"NA","Using RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ablation treatment of the lesion.",[27,58,59,60],"Cryoablation","Robotic Bronchoscopy System","Confocal Laser Endomicroscopy","NOT_YET_RECRUITING","2026-04-08",{"date":64,"type":34},"2026-04-13",{"date":66,"type":22},"2026-04-01",{"date":68,"type":22},"2026-12-31",{"name":70,"class":71},"Guangzhou Medical University","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":53,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":42},"100611016","effect-of-a-music-intervention-in-reducing-distress-and-pain-in-patients-with-lung-cancer-undergoing-mini-invasive-surgery-100611016","NCT07235098","Effect of a Music Intervention in Reducing Distress and Pain in Patients With Lung Cancer Undergoing Mini-invasive Surgery","Effect of a Music Intervention in Reducing Distress and Pain in Patients With Suspected or Diagnosed Lung Cancer Undergoing Mini-Invasive Surgery","Inclusion Criteria:\n\n* Suspected or confirmed diagnosis of lung cancer\n* Age ≥ 18 years\n* Indication for lung resection through a minimally invasive surgery\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Endocrinological disorders involving cortisol axis\n* Chronic steroid intake \\> 10 mg\u002Fday\n* Concomitant treatment with drugs against symptomatic anxiety and\u002For depression\n* Partial or complete hearing loss\n* Inability to follow the schedule of investigation\n* Patient unwilling to refrain from actively listening to other music (e.g., via other personal devices\u002Fheadphones) outside of the prescribed musical intervention defined by the study protocol during the hospitalization.",{"count":80,"type":22},74,[55],"This study aims at evaluating whether music therapy intervention is effective in decreasing psychological (distress) and physical symptoms (pain) in patients with suspected or diagnosed lung cancer undergoing minimally invasive lung surgery.",[27],[85,86,87,88],"lung cancer","pain","anxiety","music","2025-11-14",{"date":91,"type":34},"2025-11-19",{"date":93,"type":22},"2025-12-15",{"date":95,"type":22},"2027-12-31",{"name":97,"class":71},"Oncology Institute of Southern Switzerland",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":53,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100606620","monarch-robotic-bronchoscopy-for-lung-nodule-icg-dye-marking-before-vats-100606620","NCT07177924","Monarch Robotic Bronchoscopy for Lung Nodule ICG Dye Marking Before VATS","Effectiveness, Safety and Learning Curve of Monarch Robotic Assisted Bronchoscopy for Lung Nodule ICG Dye Marking Before VATS Sublobectomy","REALM","Inclusion Criteria:\n\n* Age 18-80 years\n* Clinically indicated sub-lobar resection\n* Tolerates general anesthesia\n* Single\u002Fmultiple small nodules \\\u003C20 mm in peripheral lung field\n* Nodules difficult to locate intraoperatively by inspection\u002Fpalpation\n\nExclusion Criteria:\n\n* Contraindications to bronchoscopy\u002Fanesthesia\n* Coagulopathy or bleeding tendency\n* Implanted devices interfering with navigation\n* Allergy to ICG or iodinated contrast\n* Pregnant\u002Flactating women\n* Intraoperative findings not suitable for procedure","80 Years",{"count":108,"type":22},50,[55],"This is a single-center, prospective, single-arm clinical study conducted at Beijing Cancer Hospital to evaluate the effectiveness, safety, and learning curve of preoperative indocyanine green (ICG) dye marking mixed with iodinated contrast agent under Monarch Robotic Assisted Bronchoscopy (RAB) with Cone-Beam CT (CBCT) for small pulmonary nodules that are difficult to locate during video-assisted thoracic surgery (VATS) sublobectomy. Eligible patients will undergo RAB localization immediately followed by VATS in the same operative session. The primary endpoints include the success rate of localization, effective localization, and VATS sublobar resection. Secondary endpoints include navigation success rate, operation times, reaching depth, complication rates, and health economic outcomes. The learning curve will be analyzed using the cumulative sum (CUSUM) method. A total of 50 patients will be enrolled and followed up for 14 days postoperatively.",[112,113,27,114],"Small Pulmonary Nodules","Pulmonary Nodule Localization","Video-assisted Thoracoscopic Surgery (VATS)",[116,117,118,119,120,121],"Robotic Assisted Bronchoscopy","Monarch Platform","Lung Nodule Localization","Video-Assisted Thoracoscopic Surgery (VATS)","Pulmonary Nodules","Lung Cancer Surgery","2025-09-10",{"date":124,"type":34},"2025-09-17",{"date":126,"type":22},"2025-10-10",{"date":128,"type":22},"2026-05-30",{"name":130,"class":71},"Peking University Cancer Hospital & Institute"]